This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Petereit, H. Articles by Heiss, W. Search for Related Content PubMed PubMed Citation Articles by Petereit, H. Articles by Heiss, W. Social Bookmarking                         What's this?

Interferon gamma producing blood lymphocytes are decreased by interferon beta therapy in patients with multiple sclerosis

Klinik und Poliklinik für Neurologie und Psychiatrie, Neurologie, Medizinische Einrichtungen der Universität zu Köln, Germany

S. Bamborschke

Klinik und Poliklinik für Neurologie und Psychiatrie, Neurologie, Medizinische Einrichtungen der Universität zu Köln, Germany

AD Esse

Klinik und Poliklinik für Neurologie und Psychiatrie, Neurologie, Medizinische Einrichtungen der Universität zu Köln, Germany

WD Heiss

Klinik und Poliklinik für Neurologie und Psychiatrie, Neurologie, Medizinische Einrichtungen der Universität zu Köln, Germany

Objective: We studied the individual course of interferon gamma producing blood lymphocyte count (IFGC) of 15 multiple sclerosis patients started on 8 MIU beta interferon administered subcutaneously each other day. Methods: Mononuclear blood cells were prepared before treatment and on day 3, 9, 15, as well as after month 1, 2, 3 and 4 of therapy. After stimulation intracellular interferon gamma was detected with monoclonal fluorescent antibodies and measured by flowcytometry. IFGC is given as percentage of all gated lymphocytes. Results: forty-eight hours after first interferon beta application the mean IFGC dropped significantly from 11.37 to 7.09 (P<0.05) and to 4.22 within 4 months. Whereas the majority of patients showed a decrease of IFGC from the beginning of therapy, in three of the 15 patients a transient increase of IFGC was seen suggesting a different response to immunomodulatory therapy. Conclusions: Interferon gamma producing lymphocyte count might be a useful tool to determine the biological effect of interferon β therapy in multiple sclerosis patients.

Key Words: multiple sclerosis • interferon beta therapy • interferon gamma • immunomodulatory therapy • indicator of therapeutical effectiveness

Multiple Sclerosis, Vol. 3, No. 3, 180-183 (1997)
DOI: 10.1177/135245859700300302


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H F Petereit, D Reske, R Pukrop, M Maas-Enriquez, G Japp, P J. Jongen, H W Kolmel, S Merkelbach, H P Hartung, W D Heiss, et al. No effect of intravenous immunoglobulins on cytokine-producing lymphocytes in secondary progressive multiple sclerosis Multiple Sclerosis, February 1, 2006; 12(1): 66 - 71. [Abstract] [PDF]

				H F Petereit, H Lindemann, and S Schoppe Effect of immunomodulatory drugs on in vitro production of brain-derived neurotrophic factor Multiple Sclerosis, February 1, 2003; 9(1): 16 - 20. [Abstract] [PDF]

				H F Petereit, S Nolden, S Schoppe, S Bamborschke, R Pukrop, and W D Heiss Low interferon gamma producers are better treatment responders: a two-year follow-up of interferon beta-treated multiple sclerosis patients Multiple Sclerosis, December 1, 2002; 8(6): 492 - 494. [Abstract] [PDF]

				H F Petereit, N Richter, R Pukrop, and S Bamborschke Interferon gamma production in blood lymphocytes correlates with disability score in multiple sclerosis patients Multiple Sclerosis, February 1, 2000; 6(1): 19 - 23. [Abstract] [PDF]

				A. Kracke, P. von Wussow, A. N. Al-Masri, G. Dalley, A. Windhagen, and F. Heidenreich Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS Neurology, January 11, 2000; 54(1): 193 - 193. [Abstract] [Full Text] [PDF]

				A. Gayo, L. Mozo, A. Suarez, A. Tunon, C. Lahoz, and C. Gutierrez Interferon beta-1b treatment modulates TNF{alpha} and IFN{gamma} spontaneous gene expression in MS Neurology, June 1, 1999; 52(9): 1764 - 1764. [Abstract] [Full Text] [PDF]

				P. F Smith and C. L Darlington Recent developments in drug therapy for multiple sclerosis Multiple Sclerosis, April 1, 1999; 5(2): 110 - 120. [Abstract] [PDF]

				P. Bongioanni, S. Mosti, G. Moscato, F. Lombardo, C. Manildo, and G. Meucci Decreases in T-Cell Tumor Necrosis Factor {alpha} Binding With Interferon Beta Treatment in Patients With Multiple Sclerosis Arch Neurol, January 1, 1999; 56(1): 71 - 78. [Abstract] [Full Text] [PDF]